heat shock protein
Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
ALS Biopharma will receive $250,000 to advance a heat shock protein-based biologic therapy toward eventual human trials
Posted on Monday, March 21, 2011 - 17:01, By: Miriam Davidson
UPDATE (April 9, 2012): MDA and ALS Biopharma agreed to terminate this project in April 2012, when ALS Biopharma determined that it was unable to manufacture its HSP70-based compound in a pure enough form to meet study standards. The ability to reliably produce the compound in sufficient...